FDA Leaders Name Longevity a Priority at ARDD
At a panel in Boston, senior officials announced plans to include aging in the agency's regulatory science agenda and discussed how therapies could move toward approval.
Useful takeaways from this story.
At a panel in Boston, senior officials announced plans to include aging in the agency's regulatory science agenda and discussed how therapies could move toward approval.
Longevity has a partner The 2026 edition of the Aging Research and […]
Building the complete brief
The page is ready to read now. The fuller skim-friendly version will appear here automatically.
The useful part
At a panel in Boston, senior officials announced plans to include aging in the agency's regulatory science agenda and discussed how therapies could move toward approval. Longevity has a partner The 2026 edition of the Aging Research and […]
How it works
- Longevity has a partner The 2026 edition of the Aging Research and […]
Keep reading in the app
Open the app view to save this story, compare related coverage, and continue from the same source.